Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
- Conditions
- Intrahepatic Cholangiocarcinoma
- Registration Number
- NCT04087876
- Lead Sponsor
- Basilea Pharmaceutica
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Available
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inclusion Criteria:<br><br> - all other treatment options have been exhausted<br><br> - patient is ineligible for any ongoing trials or is geographically inaccessible to<br> trials including an ongoing trial with derazantinib<br><br> - there is reason to believe that the potential benefit of receiving derazantinib<br> outweighs the risk of treatment with an investigational drug product<br><br> - patient is willing and able to provide written informed consent<br><br> - if applicable, regulatory approval by the appropriate jurisdiction is obtained
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Expanded Access
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method